Radiotherapy & Oncology
Volume 87, Issue 1 , Pages 17-23 , April 2008

Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience

  • Sonal Sura

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
    • ,
  • Vishal Gupta

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
    • ,
  • Ellen Yorke

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA
    • ,
  • Andrew Jackson

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA
    • ,
  • Howard Amols

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA
    • ,
  • Kenneth E. Rosenzweig

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
    • Corresponding Author InformationCorresponding author. Kenneth E. Rosenzweig, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA..

Received 24 April 2007 ,Accepted 3 February 2008.

References 

  1. Curran W, Scott CB, Langer CJ, et al. Long-term benefit is observed in a Phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22:621
  2. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23(25):5883–5891
  3. Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11
  4. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001;19:127–136
  5. Narayan S, Henning GT, Randall TK, et al. Results following treatment to doses of 92.4 or 102.9Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer. 2004;44:79–88
  6. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–328
  7. Rosenzweig KE, Fox JL, Leibel SA, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127
  8. Rengan R, Rosenzweig KE, Venkatraman E. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:741–747
  9. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  10. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data in 504 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  11. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1268–1279
  12. Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1258–1267
  13. Christian JA, Bedford JL, Webb S, et al. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:735–741
  14. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation therapy, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57:875–890
  15. Schwarz M, Alber M, Lebesque LV, et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:561–570
  16. Yorke E. Advantages of IMRT for dose escalation in radiation therapy for lung cancer. Med Phys. 2001;28:1291;[Abstract]
  17. Sidhu K, Ford EC, Spirou S, Yorke E, et al. Optimization with both dose–volume and biological constraints for lung IMRT. Med Phys. 2001;28:1261;[Abstract]
  18. Willner J, Baier K, Caragiani E, et al. Dose, volume, and tumor control predictions in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–389
  19. Mohan R, Barest G, Brewster LJ, et al. A comprehensive three-dimensional radiation treatment planning system. Int J Radiat Oncol Biol Phys. 1988;15:481–495
  20. Burman C, Chui CS, Kutcher G, et al. Planning, delivery and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39:863–873
  21. Spirou SV, Chui CS. A gradient inverse planning algorithm with dose–volume constraints. Med Phys. 1998;25:321–333
  22. Chui CS, LoSasso T, Spirou S, et al. Dose calculation for photon beams with intensity modulation generated by dynamic jaw or multileaf collimations. Med Phys. 1994;21:1237–1244
  23. Spirou SV, Chui CS. Generation of arbitrary intensity profiles by dynamic jaws or multileaf collimators. Med Phys. 1994;21:1031–1047
  24. Rosenzweig KE, Mychalzhak B, Fuks Z, et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer. 2000;6:82–87
  25. Lyman JT. Complication probability as assessed from dose–volume histograms. Radiat Res. 1985;104(Suppl):S13–S19
  26. Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991;21:137–146
  27. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135
  28. Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys. 1988;14:751–759
  29. Yorke E, Jackson A, Rosenzweig KE, et al. Dose–volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002;54(2 SU):329–339
  30. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  32. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21:2004–2010
  33. Yom S, Liao Z, Liu HH, et al. Analysis of acute toxicity results of intensity-modulated radiation therapy (IMRT) in the treatment of non-small cell lung cancer. Lung Cancer. 2005;49:S52;Abstract
  34. Stevens C, Guerrero T, Forster K. Lung cancer radiotherapy. In:  Palta Jatinder,  Rockwell Mackie T editor. Intensity-modulated radiation therapy: the state of the art. Madison, Wisconsin: Medical Physics Publishing; 2003;p. 645–662
  35. Seppenwoolde Y, Lebesque JV, De Jaeger KD, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2003;55:724–735
  36. Graham MV, Purdy JA, Emani B, et al. Clinical dose–volume histogram analysis for pneumonitis after 3-D treatment for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;45:323–329
  37. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1268–1279
  38. Bortfeld T, Jokivarsi K, Goitein M, et al. Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol. 2002;47:2209–2220
  39. Chui CS, Yorke ED, Hong L. The effects of intra-fraction organ motion on the delivery of intensity-modulated field with multilead collimator. Med Phys. 2003;30:1736–1746
  40. Yorke ED, Wang L, Rosenzweig KE, et al. Evaluation of deep inspiration breath hold lung treatment plans with Monte-Carlo dose calculation. Int J Radiat Oncol Biol Phys. 2002;53:1058–1070
  41. Wang L, Yorke E, Chui CS, et al. Monte-Carlo evaluation of 6MV intensity modulated radiotherapy plans for head and neck and lung treatments. Med Phys. 2002;29:2705–2717
  42. Della Biancia C, Yorke E, Chui CS, et al. Comparison of end normal inspiration and expiration for gated intensity modulated radiation therapy (IMRT) of lung cancer. Radiother Oncol. 2005;75:149–156

PII: S0167-8140(08)00087-X

doi: 10.1016/j.radonc.2008.02.005

Radiotherapy & Oncology
Volume 87, Issue 1 , Pages 17-23 , April 2008

Article Tools

* Image Usage & Resolution